Publications

  1. Lust JA , Lacy MQ , Zeldenrust SR , Witzig TE , Moon-Tasson LL, Dinarello CA, Donovan KA . Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol 2016 Jun; 91 (6):571-4 Epub 2016 Apr 13
    View PubMed
  2. Kourelis TV , Buadi FK , Kumar SK , Gertz MA , Lacy MQ , Dingli D , Go RS , Kapoor P , Lust JA , Hayman SR , Hwa Y , Rajkumar SV , Zeldenrust SR , Russell SJ , Lin Y, Leung N , Kyle RA , Gonsalves WI , Dispenzieri A . Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. Am J Hematol 2016 Jun; 91 (6):585-9 Epub 2016 Apr 13
    View PubMed
  3. Kourelis TV , Buadi FK , Gertz MA , Lacy MQ , Kumar SK , Kapoor P , Go RS , Lust JA , Hayman SR , Rajkumar V , Zeldenrust SR , Russell SJ , Dingli D , Lin Y , Leung N , Hwa YL , Gonsalves W , Kyle RA , Dispenzieri A . Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia 2016 May; 30 (5):1079-85 Epub 2015 Dec 16
    View PubMed
  4. Mullikin TC, Rajkumar SV , Dispenzieri A , Buadi FK , Lacy MQ , Lin Y, Dingli D , Go RS , Hayman SR , Zeldenrust SR , Russell SJ , Lust JA , Leung N , Kapoor P , Kyle RA , Gertz MA , Kumar SK . Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 2016 May; 91 (5):473-5 Epub 2016 Apr 06
    View PubMed
  5. Gonsalves WI , Rajkumar SV , Gertz MA , Dispenzieri A , Lacy MQ , Buadi FK , Dingli D , Go RS , Leung N , Kapoor P , Hayman SR , Lust JA , Russell SJ , Zeldenrust SR , Hwa YL , Kourelis TV , Kyle RA , Kumar SK . Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant 2016 Apr 11 [Epub ahead of print]
    View PubMed
  6. Warsame R , Kasi PM , Villasboas-Bisneto JC, Gallenberg D , Wolf R , Ward J , Matt-Hensrud N, Grethen K, Colborn L, Zeldenrust S , Lacy MQ , Thompson CA . Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation. J Oncol Pract 2016 Jan; 12 (1):e88-94 Epub 2015 Sept 15
    View PubMed
  7. Binder M , Rajkumar SV , Ketterling RP , Dispenzieri A , Lacy MQ , Gertz MA , Buadi FK , Hayman SR , Hwa YL , Zeldenrust SR , Lust JA , Russell SJ , Leung N , Kapoor P , Go RS , Gonsalves WI , Kyle RA , Kumar SK . Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J 2016; 6:e401 Epub 2016 Mar 11
    View PubMed
  8. Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2015 Nov 30.
    View PubMed
  9. Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Clin Genet. 2015 Oct; 88(4):396-400. Epub 2014 Oct 7
    View PubMed
  10. Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA. Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum. Muscle Nerve. 2015 Sep; 52(3):449-54. Epub 2015 May 14.
    View PubMed
  11. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  12. Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015 Jun; 90(6):524-8. Epub 2015 Apr 02.
    View PubMed
  13. Swiecicki PL, Zhen DB, Mauermann ML, Kyle RA, Zeldenrust SR, Grogan M, Dispenzieri A, Gertz MA. Hereditary attr amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015 Jun; 22(2):123-31.
    View PubMed
  14. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015 Mar; 90(3):181-6. Epub 2015 Jan 16.
    View PubMed
  15. Gonsalves WI , Leung N , Rajkumar SV , Dispenzieri A , Lacy MQ , Hayman SR , Buadi FK , Dingli D , Kapoor P , Go RS , Lin Y , Russell SJ , Lust JA , Zeldenrust S , Kyle RA , Gertz MA , Kumar SK . Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 2015; 5:e296 Epub 2015 Mar 20
    View PubMed
  16. Warsame R , Kumar SK , Gertz MA , Lacy MQ , Buadi FK , Hayman SR , Leung N , Dingli D , Lust JA , Ketterling RP , Lin Y , Russell S , Hwa L , Kapoor P , Go RS , Zeldenrust SR , Kyle RA , Rajkumar SV , Dispenzieri A . Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J 2015; 5:e310 Epub 2015 May 01
    View PubMed
  17. Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02.
    View PubMed
  18. Gonsalves WI , Rajkumar SV , Go RS , Dispenzieri A , Gupta V , Singh PP , Buadi FK , Lacy MQ , Kapoor P , Dingli D , Lust JA , Zeldenrust SR , Hayman SR , Kyle RA , Gertz MA , Kumar SK . Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014 Aug 7; 124 (6):907-12 Epub 2014 June 23
    View PubMed
  19. Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kurtin PJ, Grogg KL, Dogan A. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014 Jul; 99(7):1239-47. Epub 2014 Apr 18.
    View PubMed
  20. Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol. 2014 Jun; 92(6):485-90. Epub 2014 Mar 2
    View PubMed
  21. Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014 May 15; 113(10):1723-7. Epub 2014 Mar 02.
    View PubMed
  22. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May; 28(5):1122-8. Epub 2013 Oct 25.
    View PubMed
  23. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014 Apr; 2(2):113-22.
    View PubMed
  24. Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2014 Mar; 89(3):302-5. Epub 2014 Feb 18.
    View PubMed
  25. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, Grogan M, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Leung N, Russell SR, Dingli D, Lust JA, Rajkumar SV, Jaffe AS. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014 Mar; 100(5):383-8. Epub 2014 Jan 08.
    View PubMed
  26. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium. Kelly JW, Dyck PJ, Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013 Dec 25; 310(24):2658-67.
    View PubMed
  27. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013 Dec 20; 31(36):4529-35. Epub 2013 Nov 18.
    View PubMed
  28. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122(26):4172-81. Epub 2013 Oct 21.
    View PubMed
  29. Kourelis TV , Kumar SK , Gertz MA , Lacy MQ , Buadi FK , Hayman SR , Zeldenrust S , Leung N , Kyle RA , Russell S , Dingli D , Lust JA , Lin Y, Lin Y, Kapoor P , Rajkumar SV, Rajkumar SV, McCurdy A , Dispenzieri A . Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013 Dec 1; 31 (34):4319-24 Epub 2013 Oct 21
    View PubMed
  30. Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, Gertz MA, Miller FA, Bielinski SJ, Klarich KW, Scott CG, Grogan M. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013 Dec; 20(4):263-8. Epub 2013 Oct 16.
    View PubMed
  31. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, Kumar S. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 2013 Oct; 27(10):2062-6. Epub 2013 May 07.
    View PubMed
  32. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013 Jul 4; 122(1):68-73. Epub 2013 May 22.
    View PubMed
  33. D'Souza A, Theis J, Quint P, Kyle R, Gertz M, Zeldenrust S, Vrana J, Dogan A, Dispenzieri A. Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. Am J Hematol. 2013 Jul; 88(7):577-80. Epub 2013 May 30.
    View PubMed
  34. Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica. 2013 Jun; 98(6):988-92.
    View PubMed
  35. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013 May; 88(5):375-8. Epub 2013 Mar 19.
    View PubMed
  36. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76.
    View PubMed
  37. Loavenbruck AJ, Chaudhry V, Zeldenrust SR, Spinner RJ, Theis JD, Klein CJ. Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma. Muscle Nerve. 2012 Nov; 46(5):817-22.
    View PubMed
  38. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
    View PubMed
  39. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012 Jul 5; 120(1):56-62. Epub 2012 May 18.
    View PubMed
  40. Warsame R , Gertz MA , Lacy MQ , Kyle RA , Buadi F , Dingli D , Greipp PR , Hayman SR , Kumar SK , Lust JA , Russell SJ , Witzig TE , Mikhael J , Leung N , Zeldenrust SR , Rajkumar SV , Dispenzieri A . Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 2012 Jul; 87 (7):647-51 Epub 2012 May 02
    View PubMed
  41. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119(23):5397-404. Epub 2012 Apr 04.
    View PubMed
  42. Zeldenrust SR. Genotype--phenotype correlation in FAP. Amyloid. 2012 Jun; 19 Suppl 1:22-4.
    View PubMed
  43. Stangou AJ, Lobato L, Zeldenrust S, Rela M, Portmann B, Linke RP, Conceicao I, Otto G, Wilczek H, Suhr O, Azoulay D, Grateau G, Picken M, O'Grady J, Heaton N, Ericzon BG, Benson MD. Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses. Amyloid. 2012 Jun; 19 Suppl 1:81-4. Epub 2012 Apr 27.
    View PubMed
  44. Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, Ando Y, Ikeda S, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Dyck PJ, Obici L, Familial Amyloidosis Consortium. The Diflunisal Trial: study accrual and drug tolerance. Amyloid. 2012 Jun; 19(Suppl 1):37-8. Epub 2012 May 2.
    View PubMed
  45. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119(21):4860-7. Epub 2012 Apr 13.
    View PubMed
  46. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20; 30(9):989-95. Epub 2012 Feb 13.
    View PubMed
  47. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012 Mar 1; 119(9):2100-5. Epub 2012 Jan 10.
    View PubMed
  48. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119(1):44-8. Epub 2011 Nov 07.
    View PubMed
  49. Donato LJ, Zeldenrust SR, Murray DL, Katzmann JA. A 71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chem. 2011 Dec; 57(12):1645-8.
    View PubMed
  50. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27; 118(17):4663-5. Epub 2011 Aug 31.
    View PubMed
  51. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20.
    View PubMed
  52. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011 Aug 18; 118(7):1763-5. Epub 2011 Jun 14.
    View PubMed
  53. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86(8):640-5. Epub 2011 May 31.
    View PubMed
  54. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011 Jun; 26(6):2032-6. Epub 2011 May 4
    View PubMed
  55. Klein CJ, Moon JS, Mauermann ML, Zeldenrust SR, Wu Y, Dispenzieri A, Dyck PJ. The neuropathies of Waldenstrom's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011 Mar; 38(2):289-95.
    View PubMed
  56. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011 Mar; 86(3):251-5. Epub 2011 Feb 15.
    View PubMed
  57. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, Bergen HR 3rd, Zeldenrust SR, Dogan A. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011 Feb; 68(2):195-9. Epub 2010 Oct 11.
    View PubMed
  58. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011 Jan; 86(1):12-8.
    View PubMed
  59. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20.
    View PubMed
  60. Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010 Dec 9; 116(24):5126-9. Epub 2010 Aug 26.
    View PubMed
  61. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24(11):1934-9. Epub 2010 Sep 09.
    View PubMed
  62. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol. 2010 Oct; 85(10):737-40.
    View PubMed
  63. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010 Oct; 85(10):757-9.
    View PubMed
  64. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
    View PubMed
  65. Chee CE, Lacy MQ, Dogan A, Zeldenrust SR, Gertz MA. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):177-80.
    View PubMed
  66. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010 Mar; 85(3):232-8.
    View PubMed
  67. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11.
    View PubMed
  68. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec; 84(12):1095-110.
    View PubMed
  69. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29.
    View PubMed
  70. Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve. 2009 Sep; 40(3):363-70.
    View PubMed
  71. Leung N, Saucier NA, Zeldenrust SR, Gunderson HD, Cornell LD. Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. NDT Plus. 2009 Aug; 2(4):292-4. Epub 2009 Apr 15.
    View PubMed
  72. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26.
    View PubMed
  73. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep. 2009 Apr; 4(2):91-8.
    View PubMed
  74. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94(3):380-6. Epub 2009 Feb 11.
    View PubMed
  75. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009 Feb; 84(2):114-22.
    View PubMed
  76. Fervenza FC, Croatt AJ, Bittar CM, Rosenthal DW, Lager DJ, Leung N, Zeldenrust SR, Nath KA. Induction of heme oxygenase-1 and ferritin in the kidney in warm antibody hemolytic anemia. Am J Kidney Dis. 2008 Nov; 52(5):972-7. Epub 2008 Sep 21.
    View PubMed
  77. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83(11):840-1.
    View PubMed
  78. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008 Sep 1; 112(5):1931-41. Epub 2008 Jun 20.
    View PubMed
  79. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun; 73(11):1282-8. Epub 2008 Apr 02.
    View PubMed
  80. Garces-Sanchez M, Dyck PJ, Kyle RA, Zeldenrust S, Wu Y, Ladha SS, Klein CJ. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008 Apr; 37(4):490-5.
    View PubMed
  81. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1; 111(5):2516-20. Epub 2007 Nov 01.
    View PubMed
  82. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008 Mar; 83(3):297-303.
    View PubMed
  83. Kaplan B, Ramirez-Alvarado M, Dispenzieri A, Zeldenrust SR, Leung N, Livneh A, Gallo G. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med. 2008; 46(3):335-41.
    View PubMed
  84. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82(10):1179-84.
    View PubMed
  85. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
  86. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82(3):323-41.
    View PubMed
  87. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15; 109(2):465-70. Epub 2006 Sep 28.
    View PubMed
  88. Ladha SS, Dyck PJ, Spinner RJ, Perez DG, Zeldenrust SR, Amrami KK, Solomon A, Klein CJ. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst. 2006 Dec; 11(4):346-52.
    View PubMed
  89. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64. Epub 2006 Jul 13.
    View PubMed
  90. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81(8):1047-53.
    View PubMed
  91. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006 May 1; 107(9):3669-75. Epub 2005 Dec 22.
    View PubMed
  92. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107(8):3378-83. Epub 2006 Jan 05.
    View PubMed
  93. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133(2):158-64.
    View PubMed
  94. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106(13):4050-3. Epub 2005 Aug 23.
    View PubMed
  95. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15; 22(18):3751-7.
    View PubMed
  96. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104(6):1881-7. Epub 2004 Mar 25.
    View PubMed
  97. Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR, Zeldenrust SR. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization Fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem. 2004 Sep; 50(9):1535-43.
    View PubMed
  98. Bergen HR, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJB, Klein CJ, O'Brien JF, Thibodeau SN, Muddiman DC. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clinical Chemistry. 2004 Sep; 50(9):1544-52.
    View PubMed
  99. Miller DV, McClure RF, Crawford BG, Zeldenrust SR, Leibovich BC, Sebo TJ. Histiocytes containing immunoglobulin crystals in the urine of a patient with IgA kappa plasmacytoma of the bladder. Diagn Cytopathol. 2004 Jul; 31(1):48-51.
    View PubMed
  100. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103(10):3960-3.
    View PubMed
  101. Sharma P, Perri RE, Sirven JE, Zeldenrust SR, Brandhagen DJ, Rosen CB, Douglas DD, Mulligan DC, Rakela J, Wiesner RH, Balan V. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl. 2003 Dec; 9(12):1273-80.
    View PubMed
  102. Bergen HR, Zeldenrust SR, Naylor S. An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid. 2003 Sep; 10(3):190-7.
    View PubMed
  103. Zeldenrust S, Gertz M, Uemichi T, Bjornsson J, Wiesner R, Schwab T, Benson M. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation. 2003 Feb 27; 75(4):560-1.
    View PubMed
  104. Soares-Welch CV, Zeldenrust SR, Conover CA, Grant CS, Service FJ. Hodgkin's lymphoma manifesting with hypoglycemia. Endocr Pract. 2003 Jan-Feb; 9(1):96-7.
    View PubMed
  105. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies - Case 2. Marantic endocarditis in advanced cancer. J Clin Oncol. 2002 Oct 1; 20(19):4111-4.
    View PubMed
  106. Farlow M, Murrell J, Ghetti B, Unverzagt F, Zeldenrust S, Benson MD. Clinical characteristics in a kindred with early onset Alzheimer's disease and their linkage to a G to T change at position 2149 of amyloid-precursor protein. Neurology. 1994; 44:105-11.
    View PubMed
  107. Zeldenrust SR, Skinner M, Harding J, Skare J, Benson MD. A new transthyretin variant (His-69) associated with vitreous amyloid in an FAP family. Amyloid Int J Exp & Clin Inv. 1994; 1(1):17-22.
  108. Zeldenrust S, Benson MD. A new test for detection of the His 58 variant transthyretin allele in hereditary amyloidosis - creation of diagnostic restriction endonuclease recognition site by PCR based mutagenesis. Amyloid Int J Exp & Clin Inv. 1994; 1(3):154-9.
  109. Benson III MD, Julien J, Liepnieks J, Zeldenrust S, Benson MD. A transthyretin variant (Alanine 71,49) associated with familial amyloidotic polyneuropathy in a French family. J Med Genet. 1993; 30:117-22.
    View PubMed
  110. Zeldenrust SR, Murrel J, Farlow M, Ghetti B, Roses AD, Benson Md. RFLP analysis for APP 717 mutations associated with Alzheimer's disease. J Med Genet. 1993; 30:476-8.
    View PubMed
  111. Uemichi T, Murrel JR, Zeldenrust S, Benson MD. A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy. J Med Genet. 1992; 29:888-91.
    View PubMed